Literature DB >> 19481905

Cleft soft palate reconstruction: prospective study on infection and antibiotics.

H P Mÿburgh1, K-W Bütow.   

Abstract

The aim of this prospective study was to identify possible pathogenic organisms associated with wound complications in the form of wound infections, wound breakdown and the formation of oro-nasal fistulas. The organisms' resistance profile to antibiotics was also evaluated. This prospective study consisted of the evaluation of the intra-oral microbiological profile of 100 babies with soft palate cleft deformities peri-operatively. A wide spectrum of pathogenic organisms from the upper aero-digestive track was isolated, as well as a group of organisms that originated from the colon/perineum. The latter organisms were mostly associated with postoperative complications. The antibiotic resistance profile showed a high resistance to commonly used antibiotics such as ampicillin, amoxycillin-clavulanic acid, and first- and second-generation cephalosporins. The resistance profile of the organisms needs to be reassessed and appropriate antibiotics must be used in combination with an antimicrobial mouth rinse.

Entities:  

Mesh:

Year:  2009        PMID: 19481905     DOI: 10.1016/j.ijom.2009.04.022

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  3 in total

Review 1.  Flap Necrosis after Palatoplasty in Patients with Cleft Palate.

Authors:  Percy Rossell-Perry
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

2.  A Comparative Study of Oral Microbiota in Infants with Complete Cleft Lip and Palate or Cleft Soft Palate.

Authors:  Agnieszka Machorowska-Pieniążek; Anna Mertas; Małgorzata Skucha-Nowak; Marta Tanasiewicz; Tadeusz Morawiec
Journal:  Biomed Res Int       Date:  2017-03-14       Impact factor: 3.411

3.  The spectrum of intraoral bacteria seen in patients with cleft palates in an African setting.

Authors:  Shaal Ramdial; Anil Madaree
Journal:  Microbiologyopen       Date:  2018-06-27       Impact factor: 3.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.